formoterol, glycopyrronium bromide, budesonide - Sökresultat

Europeiska unionen - svenska - EMA (European Medicines Agency)

trixeo aerosphere

astrazeneca ab - formoterol fumarate dihydrate, glycopyrronium bromide, budesonide - pulmonell sjukdom, kronisk obstruktiv - läkemedel mot obstruktiv lungsjukdom, - trixeo aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long acting beta2 agonist or combination of a long-acting beta2 agonist and a long acting muscarinic antagonist.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

formoterol novolizer 6 mikrogram/dos inhalationspulver

meda ab - formoterolfumaratdihydrat - inhalationspulver - 6 mikrogram/dos - formoterolfumaratdihydrat 6 mikrog aktiv substans; laktosmonohydrat hjälpämne - formoterol

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

formoterol novolizer 12 mikrogram/dos inhalationspulver

meda ab - formoterolfumaratdihydrat - inhalationspulver - 12 mikrogram/dos - laktosmonohydrat hjälpämne; formoterolfumaratdihydrat 12 mikrog aktiv substans - formoterol

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

formoterol generics 12 mikrogram inhalationspulver, hård kapsel

mylan ab - formoterolfumaratdihydrat - inhalationspulver, hård kapsel - 12 mikrogram - laktosmonohydrat hjälpämne; formoterolfumaratdihydrat 0,012 mg aktiv substans - formoterol

Europeiska unionen - svenska - EMA (European Medicines Agency)

riltrava aerosphere

astrazeneca ab - budesonide, formoterol fumarate dihydrate, glycopyrronium bromide - pulmonell sjukdom, kronisk obstruktiv - läkemedel mot obstruktiv lungsjukdom, - riltrava aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2 agonist or combination of a long-acting beta2 agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)